SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 30, 2014
Agios Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
|38 Sidney Street, 2nd Floor, Cambridge, MA||02139|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants telephone number, including area code: (617) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 5.07 Submission of Matters to a Vote of Security Holders.
Agios Pharmaceuticals, Inc. (the Company) held its Annual Meeting of Stockholders on May 30, 2014. The following is a summary of the matters voted on at that meeting.
|1.||The Companys stockholders elected Dr. Lewis C. Cantley, Paul J. Clancy and Perry Karsen as class I directors to serve until the 2017 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders vote with respect to the election of such class I directors were as follows:|
Dr. Lewis C. Cantley
Paul J. Clancy
|2.||The Companys stockholders ratified the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the current fiscal year. The results of the stockholders vote with respect to such ratification were as follows:|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|AGIOS PHARMACEUTICALS, INC.|
|Date: June 3, 2014||By:|
David P. Schenkein, M.D.
Chief Executive Officer